EL KENDI PRODUCT

ALGERIAN QUALITY GENERIC

May 18th 2022

El Djazair Healthcare
Dakar, Senegal
2
MS PHARMA GROUP
PRESENTATION
MS Pharma is well positioned for growth in current
and new markets
Our Footprint ZUG
Management
Office
Strong sales & marketing network
in MENA markets

Broad product portfolio in key

therapeutic areas: Cardio, CNS,
Rheumatology, Urology, Dermatology,
Anti-infectives, Respiratory, Oncology,
and others

3 R&D centers in MENA

Development and production capabilities
in many dosage forms: SOD’s, injectables,
liquids, creams, ointments

5 manufacturing facilities in 4 countries

cGMP-production sites in Jordan, Algeria,
Turkey, and Saudi.

4
Our aspiration is to be among the top 5
Pharmaceutical companies in MENA by 2025
MS Pharma’s
Strong base
Leading regional pharma company,
strongly rooted in the MENA
Strong marketing capabilities
and brand recognition
Successful R&D, local production, and
market access capabilities in MENA
Own sales force in key
markets, in total >500 FTE
MS Pharma’s
Strategic priorities
To grow oncology & biosimilars portfolio, add
innovative products.
Grow KSA business with selected portfolio utilizing
local manufacturing.
Investing in UAE & Iraq to support the planned growth.
Explore on all regional tender opportunity.
Utilize manufacturing capabilities to serve European
B2B markets.
5
One of the fastest growing companies
in the MENA region

Over 300 INNs / Over 2400

Historical CAGR of molecules Employees
23% over the past 8 years. 47 new INNs within
Projected CAGR of 28% our pipeline
2021 revenue is
driven by strong organic 48 INNs under
$220 Million
growth and new growth Registration
initiatives.

6
International management team
with management office in Zug, Switzerland

Adam Dimitropoulos Stefan Busemann Marc Westermann Sofiane Achi Arni Haraldsson
CFO EVP Business EVP Commercial GM EL KENDI EVP SCM
Development META

STADA, Amneal, STADA, Sandoz, Wörwag Pharma, Boehringer Xantis Pharma,

Actavis Sanofi Generics, Novartis/Sandoz, Ingelheim, Sanofi Actavis
Actavis, Ratio Mepha, Abott,
Kalle Känd pharm, 4SC Mylan
CEO

Acino, Takeda,
Nycomed, Menarini

Yazan Al Tamimi Joao Keller Nouha Aissat

Shadi Madieh
EVP QA EVP Technical
EVP R&D VP Commercial
Operations Operations El KENDI

Tabuk, Hikma STADA, Sandoz, Hikma EL KENDI,

Pharmaceutical, Actavis Pharmaceuticals, Ival Pharma
Aramco-Petro GlaxoSmithKline
Rabigh.
7
Our global production network – GMP
Turkey
One sterile
manufacturing facility

Jordan X2
Two plants, one sterile,
one general OSD
• Algeria including a
Algeria cephalosporin facility
• North & West Africa
One local
manufacturing facility

KSA
Saudi Arabia
One local secondary
packaging facility

8
3 R&D centers in MENA

MS Pharma’s dedicated R&D team has Over 2000 Marketing Authorizations.

significant experience in formulation and
development of various dosage forms:
47 new INNs/ molecules
• Simple oral dosage forms within our pipeline.
• Complex solid dosage forms
• Topical (Ointments and gels)
48 INNs/Molecules
• Simple sterile liquids (Vials,
under registration.
ampoules, Pre-filled syringes)
• Complex injectables

Focus on chronic diseases.

One of the most robust and differentiated

product portfolios in the region.

9
Our strong pipeline and portfolio covers
specialized therapeutic areas
Others
Over 95% of MS Pharma’s revenues are derived
from the company’s proprietary brands 27%

40% CVS
Hx Portfolio
Solutions 4% Split
10%

19%

Oncology
CNS
MS Pharma
96.7% Proprietary Our strategic focus is on:
Brands
1. Our core existing products CNS & CVS
1.9% Third Party
brands
2. Oncology & Immunomodulators products.
1.4%
CMO
Our target is to grow from 10% today to 15% in 2025
Updated in Aug 2020
10
MS Pharma differentiates its portfolio
by focusing on complex formulations and technologies
MS Pharma aims to continuously expand and
improve its product offerings to its customers.

New Chemical Entities (NCE)

Biosimilars/Complex

Added-value generics

New generics “First-to-Market Gx”

Plain generics

11
EL KENDI
EL KENDI in few words…

15 years of success

2009 2015
El Kendi site set up 1st local manufacturer
in Algeria

Created in 2010 2022

2007 Launch of products More than 200 SKU’s
Ambitious investment dedicated to chronic commercialized
diseases
El Kendi industrial set up in Algeria

One of the first employers Capacity

One of the biggest private Site approved in different
in Pharmaceutical industry
investments >70M$ countries 100 M Packs/ Year
with > 1000 employees

➢ Manufacturing site established since 2009

➢ Approved by several regulation bodies: Congo, Ivory Cost, Sudan & Libya
➢ Regulatory procedures undergoing for additional approvals/ certifications (EU GMP/ WHO)
➢ More than 250 valid marketing approvals in Algeria, including several 1st Generic or First To Market

➢ 150 dossiers under development with a special focus on innovative molecules

14
Capacity of 100 M Packs

High technology equipements for

production & QC Lab

57% Solid forms

22% Liquid
21% Semi-solid

15
El Kendi Manufacturing Lines
2 Liquid lines (oral suspensions & syrups) 2 Semi solid lines (ointments & creams)

3 Solid Lines (Tablets, Capsules)

16
High Quality Standards= Better Patient Care
Human Resources: • 13% of employees in quality division (128)
• Regular GMP Trainings

Standard Operating • European guidelines, ICH, Pharmacopoeias, etc.

Procedures: • Pharmacovigilance
• Customer Complaint
• Batch recall

Maufacturing Equip.: Manuf Line Suppplier Origin

Yenchen Taiwan
Tab/ Caps
Fette / Uhlmann / Bosch Germany
Liquid Olsa / Bosch Germany
Semi-Solid Olsa / Norden Italy / Sweden

QC Lab.: Equipment Brand Origin

HPLC (16) & 3 UPLC/ 1 U-HPLC-Arc Waters USA

Gas chromatography Shimadzu Japan
Chambres Climatiques Binder Germany
UV VIS spectrophotometers Agilent USA
IR spectrophotometers Shimadzu Japan

17
El Kendi Leader in areas where we operate
Rank by BU – Cardiovascular Rank by BU – CNS
Brand INN Sales MS Packs- 2021 Packs 2021

PHARMALLIANCE BEKER

ASTRAZENECA HIKMA PHARMA

HIKMA PHARMA SANOFI

SANOFI BIOGALENIC

EL KENDI 14245 062 EL KENDI 4888 646

More than 1.3 More than 3,7

Million Million
patients patients

Rank by BU – Urology
Packs- 2021 Rank by BU – Rheumatology
Packs- 2021
BEKER
WOO-SHIN MEDIC
PHARMALLIANCE
HIKMA PHARMA
SAIDAL
BIOPHARM
BIOPHARM SAIDAL

EL KENDI 4326924 EL KENDI 9953043

Top 20 El Kendi Products

IQVIA- Year 2021 IQVIA YEAR 2021- ATC4 Covered by El Kendi
Our People who make the difference
Talented & Experimented team with a
management mainly having MTN
background
75% Less than 40 years old (global
medium age: 38 years)
Training & Development Programs part
of El Kendi Culture
A work environment that promotes
employee well-being and stability
65% of employees have more than 5
years' experience at El Kendi (global
average experience 7 years)
El Kendi won the Best Employer Award
for 2018 in the "Best Places to Work"
program.
19
EL KENDI COMMITMENT TO HCP’s &
COMMUNITIES
 Training program
in Cardiology

Cardiologist training on Hospital Immersion Internships

echo-doppler for hypertension management
WS on congenital cardiac
Over 1000 diseases
HCPs trained

Postgraduate training for GP’s Cardiologist training rythmology

Training program in CNS & Primary Care
CNS Primary Care

1st digital event in Algeria

presentation of an innovative digital solution Etofan (Etoricoxib) launch: organization of the 1st pain forum for
Rhumato/ Ortho & Physio. With contribution of international & national
presence of 300 hcps (psychiatrists, neurologists and pharmacists)
KOL’s (Pr Chevalier –France- Dr AL DAWOOD –Jordan- & Pr. Djoudi-Algeria)

Certified training in 2 modules on Mindfulness Meditation

Osteoarticular echography training in different hospitals
22
 Improving the quality of lives
goes beyond products …
• By supporting and helping our communities, we have proven to be a community-engaged company and
have built a strong reputation in all our countries of operation.

23
El Kendi in a nutshell
• Access of large number of patients to new therapies in chronic diseases and cancer at affordable prices

• Leading generics manufacturer with high quality standards & solid expertise from the licensing, R&D, till
commercialization & distribution.

• Wide network of partners and regional agreements through the group (licences and technology transfers
which offer a large access to innovative medicines)

• Targeted therapeutic focus (CVS, CNS, Uro, Rheumato, Dermato, Onco, Diab)

• Scientific engagement through partnership with HCOs and the Medical Continuing Education with HCP's

• Cohesive & ambitious development strategy with high added value & differentiation projects

• Concrete steps into export and international partnerships in the region

24
The ingredients for a high quality product

Partnerships

25
THANK YOU